TG101348

Name: TG101348
SKU: T2404
Availability: InStock

Product ID T2404

Cas No. 936091-26-8

Purity ≥98%

Product Unit Size	Cost	Quantity		Stock

Bulk Quote

Quicklinks

Description
Product Info
Shipping and Storage
Downloads
References

Description

TG101348 is an inhibitor of JAK2 that is currently in clinical trials as a potential treatment for myelofibrosis. TG101348 exhibits immunomodulatory and anticancer chemotherapeutic activities. In cells acquired from acute coronary syndrome patients, TG101348 decreases expression of Th17 cells and increases expression of Treg cells. TG101348 inhibits cellular proliferation of Hodgkin lymphoma cells and mediastinal large B-cell lymphoma cells; in vivo, this compound decreases tumor growth and increases survival. In animal models of myeloproliferative disease, TG101348 decreases hematocrit and leukocyte count, somewhat attenuating myelofibrosis.

Product Info

Cas No.	936091-26-8
Purity	≥98%
Formula	C₂₇H₃₆N₆O₃S
Formula Wt.	524.68
IUPAC Name	N-(2-Methyl-2-propanyl)-3-{[5-methyl-2-({4-[2-(1-pyrrolidinyl)ethoxy]phenyl}amino)-4-pyrimidinyl]amino}benzenesulfonamide
Synonym	SAR302503, Fedratinib
Solubility	DMSO 100 mg/mL (190.59 mM) Water Insoluble Ethanol Insoluble
Appearance	White to off white powder

Shipping and Storage

Store Temp	-20°C
Ship Temp	Ambient

Downloads

MSDS	T2404 MSDS PDF
Info Sheet	T2404 Info Sheet PDF

References

Zheng Y, Wang Z, Deng L, et al. Modulation of STAT3 and STAT5 activity rectifies the imbalance of Th17 and Treg cells in patients with acute coronary syndrome. Clin Immunol. 2015 Jan 5;157(1):65-77. PMID: 25572535.

Hao Y, Chapuy B, Monti S, et al. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin Cancer Res. 2014 May 15;20(10):2674-83. PMID: 24610827.

Zhang M, Xu CR, Shamiyeh E, et al. A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers. J Clin Pharmacol. 2014 Apr;54(4):415-21. PMID: 24165976.

Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008 Apr;13(4):311-20. PMID: 18394554.

Custom Order

Name*
First Last
Company/Institution
Email*
Enter Email Confirm Email
Product ID
Product Name
Unit Size
Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
Unit Label
Quantity
Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
Comments
Comments
This field is for validation purposes and should be left unchanged.

TG101348

Quicklinks

Description

Product Info

Shipping and Storage

Downloads

References

Custom Order

Related Products

Troglitazone

L-(+)-Alliin

Clindamycin Phosphate

Thienylethyl Isothiocyanate

Dihydrotanshinone

Bisdemethoxycurcumin

Granuliberin R

Destruxin A

Clofibric Acid

Perifosine

Hexarelin

Taxinin M

Clopidogrel Sulfate

Lactacystin

Ligustrazine Hydrochloride

Se-Methylseleno-L-cysteine

Voriconazole

NU-2058

Geniposidic Acid

T2 Toxin

Footer